Also: With a grin — and tight lips — Revolution Medicines' CEO faces questions about acquisition
In case you missed it - Investor behind Moderna says U.S. policy is "taking a sledgehammer to our miracle machine," STAT
- At JPM, doctors' darling OpenEvidence says it's pursuing "medical super-intelligence," STAT
- In China, AI is finding deadly tumors that doctors might miss, New York Times
- FDA declines to approve Atara's therapy for rare blood cancer, Reuters
|
|
Check out more exclusive coverage with a STAT+ subscription | Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles. |
|
| STAT, 1 Exchange Place, Boston, MA | ©2026, All Rights Reserved. | |
|
No comments